Baron Capital , an investment management company, released its Q3 2026 investor letter for the "Baron Health Care Fund". The letter can be downloaded here . During the quarter ended September 30, 2026, Baron Health Care Fund® advanced 4.02%, underperforming the Russell 3000 Health Care Index's 6.19% gain. Since its inception, the Fund's annualized growth is 10.80%, slightly above the Benchmark. Disappointing stock selection, particularly in biotechnology, contributed to the Fund trailing the Benchmark by 217 basis points. The strategy focuses on identifying growth companies in health care with strong management and competitive advantages. The health care sector is projected to present attractive investment opportunities due to its complexity and ongoing changes. Encouraging results from life sciences tools and advancing technology, like AI in drug discovery, are seen as key growth drivers. The long-term outlook for health care remains positive, supported by demographic trends and ongoing advancements in technology. Also, check the Fund's top five holdings to see its best picks for 2026.
In its Q3 2026 investor letter, Baron Health Care Fund noted Merck & Co., Inc. (NYSE: MRK ). Merck & Co., Inc. (NYSE:MRK) is a leading healthcare company that offers human health pharmaceuticals for various areas. On November 04, 2026, Merck & Co., Inc. (NYSE:MRK) closed at $150.36 per share with a market capitalization of $370.96 billion. Over the past month, Merck & Co., Inc. (NYSE:MRK) returned 4.88% and its shares gained 74.08% over the past 52 weeks.
Baron Health Care Fund stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its Q3 2026 investor letter:
We added to positions in Johnson & Johnson (J&J), Merck & Co., Inc. (NYSE:MRK), and Vertex Pharmaceuticals Incorporated. Merck has been proactively managing the anticipated loss of exclusivity for Keytruda through aggressive business development and pipeline investment.
FREE REPORT: What are billionaires buying right now?While we acknowledge the potential of ELAN as an investment, you should take a look at these billionaire-backed stocks before making your next move. Insider Monkey just released an exclusive look into the hidden portfolios of the world's top fund managers. Get instant, free access to the " 7 Stocks Warren Buffett & Billionaires Are Quietly Hoarding" report and join 2.5 million monthly readers leveraging elite hedge fund data to build wealth. Get it NOW!
In another article , we discussed Merck & Co., Inc. (NYSE:MRK) and shared Auxier Asset Management's views on the company. In addition, please check out our hedge fund investor letters Q3 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years .
This article is originally published at Insider Monkey .
